How do you decide if a CRO advisory before a full-time hire is right for a Series A company when pipeline coverage below 2x?

What a CRO advisory actually is at this stage and why the coverage number forces the question

A CRO advisory at Series A is a part-time senior revenue operator — typically 15–40 hours per month, engaged on a 60–90 day term — whose deliverable is a diagnosis and an operating system, not closed revenue. This is a different product from a full-time Chief Revenue Officer. The full-time CRO is a builder: they hire, own a number, sit on the leadership team, and are measured over four to six quarters. The advisory is a fixer and a mirror: they audit the existing motion, tell you what is actually broken, install a minimum viable process, and then either hand it off or make the case for a permanent hire. Conflating the two is the single most expensive mistake at this stage, because you buy a twelve-month bet when what you needed was a ninety-day answer.

Pipeline coverage forces the question because it is the only forward-looking number a Series A board trusts. Coverage is open pipeline in a period divided by the quota or plan for that period. At a healthy 25–30% stage-weighted win rate, you need roughly 3–4x coverage to land the number with confidence. At 2x you are betting on a 50% win rate, which almost no early-stage company sustains. Below 2x, the arithmetic says you will miss unless something structural changes — and the missing information is not "how much do we need," it is "why is it thin."

That "why" splits three ways, and each way implies a completely different spend. If the top of the funnel is starving — say, fewer than 40–50 qualified opportunities created per quarter against a plan that needs 90 — you have a demand problem, and the correct next hire is often a demand-generation leader or an SDR pod, not a CRO at all. If opportunities are being created at volume but stalling — 30–40% of open deals sitting past 60 days with no next step booked — you have a velocity and process problem, which an advisory can materially fix inside one quarter. And if deals are entering the funnel and dying at "we don't have budget for this," you have a qualification problem masquerading as a coverage problem, where roughly half the reported pipeline was never real and the true coverage was closer to 1x all along.

This is also where RevOps discipline separates a real diagnosis from a vibes-based one. Coverage is only as trustworthy as the stage definitions underneath it. Most Series A CRMs have exit criteria that are aspirational at best — "Discovery" means someone took a call, "Proposal" means someone asked for pricing. Before an advisory can tell you whether coverage is 1.4x or 2.1x, they have to re-baseline what a stage means and re-score the open set against it. Expect the honest number after that exercise to be 20–35% lower than what the dashboard was reporting. Founders find this brutal. It is also the first genuinely useful thing the engagement produces.

The strategic argument for the advisory is that it converts an irreversible decision into a reversible one. A full-time CRO hire is roughly a $250K–$400K total-comp commitment plus 0.5–1.5% equity, a 60–120 day search, a 90-day ramp, and — if it fails — a severance conversation and another two quarters lost. That is nine to twelve months of company time riding on a hypothesis you have not yet tested. The advisory tests the hypothesis for a fraction of the cost and produces the exact artifact the search needs: a scorecard describing the specific leader this specific motion requires.

The step-by-step process for running the decision

Treat this as a structured sequence, not a hiring impulse. The process below is what a competent advisory runs, and it is also the process you should evaluate them against before signing.

Week 0 — re-baseline the number. Pull every open opportunity. For each, record: created date, current stage, days in current stage, last meaningful buyer-side activity, the named economic buyer, and the specific next step with a date on the calendar. Any deal with no buyer-side activity in 30 days and no scheduled next step is a zombie. Strip zombies out and recompute coverage. This alone typically moves a "1.9x" to something in the 1.2–1.5x range and tells you the real starting point.

Weeks 1–4 — the pipeline autopsy. Categorize every stalled deal by the reason it stalled: no budget, no authority, no compelling event, feature gap, lost to competitor, or went dark. Run structured loss interviews on the last 10–15 deals that reached demo and did not close. The pattern in those interviews is the diagnosis. If 7 of 10 cite budget or timing, it is qualification. If 7 of 10 cite feature gaps or a competitor, you have a product or positioning issue and no CRO of any kind fixes that. Simultaneously compute stage-to-stage conversion and median days-in-stage. Demo-to-close above 25% means the product lands and the leak is upstream; below 15% means the problem is not the sales team.

Weeks 4–8 — the process reset. Install four qualification criteria, not fifteen — a stripped MEDDIC or BANT works fine, but the criteria must be evidence-based, not opinion-based. "Economic buyer identified" means you have their name and have met them, not that the champion mentioned a VP exists. Impose a next-step rule: no deal stays in the forecast without a mutually scheduled next action. A useful forcing function is a 7-day rule from demo to proposal — if a deal cannot advance within a week of the demo, the rep re-qualifies authority and timeline rather than letting it drift. Run a weekly forecast call where reps present evidence, not confidence.

Weeks 8–12 — the recommendation. By the end of the term the advisory should hand the board three things: the true coverage trend line across the engagement, the ranked leak list with what was fixed and what remains, and an explicit build-or-hold call with a scorecard for the hire if the answer is build.

Costs, timelines, and typical ranges

The cost comparison is what makes this decision tractable, and it is worth doing in actual dollars against your actual burn rather than in the abstract.

A fractional or advisory engagement at this level generally prices in one of three shapes. Retainer is most common: a fixed monthly fee for a defined time commitment, usually structured around one to two days per week. Day-rate engagements exist for pure diagnostic work with a hard scope. Project-based pricing shows up when the deliverable is narrow — a pipeline audit, a comp plan rebuild, a forecast process. Terms are typically 60–90 days with a 30-day out, and you should insist on the out clause; an advisory unwilling to be fired in thirty days is selling a subscription, not a diagnosis.

A full-time Series A CRO is a different order of magnitude. Total cash comp commonly lands in the $250K–$400K range depending on market and stage, typically split 50/50 or 60/40 base to variable, plus equity in the 0.5–1.5% band with a four-year vest and a one-year cliff. Layer on recruiting — either a contingency fee around 20–25% of first-year cash or a retained search — and the fully loaded first-year cost is meaningfully above the headline number. Then add time: 60–120 days to source and close a credible candidate, 30 days of notice at their current job, and 90 days before they are operating independently. From decision to impact is realistically six to nine months.

Against a $150K–$250K monthly burn, an advisory is roughly 1–2% of monthly spend. A full-time CRO is 5–8% of annual runway consumed in year one. The asymmetry is the argument. If you have 18+ months of runway, a proven repeatable motion, and a founder ready to hand over the number, the full-time hire is straightforwardly correct and delay costs you compounding. If you have under 12 months, the advisory is the only responsible move, because a failed CRO hire at 10 months of runway is an extinction event — you lose the cash, you lose the two quarters, and you enter a bridge conversation with a worse story than you started with.

On timeline expectations for the advisory itself: do not expect coverage to move in the first 30 days. Days 1–30 produce a diagnosis and usually a *worse-looking* number as zombies get purged. Days 30–60 produce process change and early velocity gains — the most common first win is compressing days-in-stage post-demo, which can move 20–30% on a disciplined next-step rule alone. Days 60–90 produce a coverage trend, not a coverage destination. If your sales cycle is 90 days, a fix applied in week six literally cannot show up in closed revenue inside the engagement, and any advisory who promises otherwise is either discounting into the number or padding the pipeline. Judge them on leading indicators: opportunity creation rate, stage conversion, days-in-stage, forecast accuracy versus actual.

One structural note on incentives. It is reasonable and common to write a conversion provision into the advisory agreement — a defined fee or credit if the company hires the advisor full-time within some window. Get it in writing at the start. Negotiating it after ninety days of good work, when both sides are emotionally committed, is where relationships sour.

Where teams get it wrong

Hiring a builder to do a fixer's job. The most common failure is running a full-time CRO search while coverage is below 2x and the cause is unknown. You end up writing a job description that says "build a scalable revenue engine" and hiring someone whose actual first task is forensic — and senior builders are frequently bad at forensics, or unwilling to spend their first quarter doing it. The role you posted and the role that exists are different jobs.

Treating a volume problem as a leadership problem. If you are creating 30 qualified opportunities a quarter against a plan needing 90, no revenue leader closes that gap through sales management. Adding a $300K CRO on top of an empty funnel produces an expensive person watching an empty funnel. This is the case where the honest advisory tells you not to hire them or anyone like them, and instead points you at demand generation. An advisory unwilling to give that answer is not worth engaging.

Measuring the advisory on bookings. Founders under board pressure often push the advisory to close deals personally. It feels productive and it destroys the value of the engagement — you have converted your diagnostician into your best rep, and when they leave in 90 days the diagnosis never happened and the pipeline reverts. Deal reviews and live-call coaching are in scope. Carrying a bag is not.

Leaving the founder-as-closer dynamic untouched. At Series A the founder typically closes 50–70% of revenue. That is not automatically bad. The failure is not distinguishing bottleneck from asset. A founder who is a bottleneck spends most of their week on demos that a trained rep could run, and the fix is to document their objection handling, pricing logic, and closing sequence into a playbook someone else can execute, then set an escalation rule so the founder only enters deals above a specific ACV threshold or after a rep has genuinely exhausted their options. A founder who is a genuine asset — because deals close on their domain credibility or relationships — should not be removed from selling; they should be surrounded with support so their time concentrates on the top handful of deals.

Keeping gut-feel forecasting. The spreadsheet where probability is set by feel is nearly universal at this stage and it is why boards get surprised. Gut-feel forecasts miss badly and asymmetrically — always optimistic, never the other way. Replacing it with stage-gate criteria where advancement requires a specific evidenced event tightens accuracy substantially, and it is the change founders resist hardest because it feels like bureaucracy imposed on relationships they understand. Show them the delta between forecast and actual over the last three quarters; the argument usually ends there.

Running an advisory with no exit criteria. Write down at the start what "this worked" means: coverage above a stated threshold, a documented playbook, a defined forecast accuracy band, a first sales hire ramped. Without those, ninety days becomes six months becomes a permanent part-time CRO who is neither cheap nor accountable — the worst of both structures.

Not fixing the data layer. If the CRM cannot produce coverage by rep, by segment, and by stage without manual assembly, every subsequent decision runs on assembled anecdote. Clean stage definitions, required fields at stage exit, and a single agreed source for the number are unglamorous RevOps work that must precede the interesting work.

Ignoring the board narrative. The advisory should be producing a short, regular written update to the board: true coverage by rep and segment, the ranked stall reasons with evidence from actual deal reviews, and a standing build-or-hold recommendation. If coverage is under 1.5x, the board needs to hear that the quarter is at material risk early enough to act, not in week eleven.

Decision framework: when to choose what

Run the decision against four gates in order. Failing an earlier gate makes the later ones irrelevant.

Gate one — is it a revenue problem at all? If loss interviews cluster on feature gaps and competitor wins, and demo-to-close is under 15%, this is product-market fit. Neither an advisory nor a CRO fixes it, and hiring either burns cash while the real work goes undone. Route to product, tighten the ICP, and revisit.

Gate two — is it volume or process? Compare opportunities created against what the plan requires. Materially short on creation means demand generation is the constraint and the hire order changes. At or near target creation with deals stalling means process, which is exactly what an advisory is built to fix.

Gate three — what does runway permit? Under 8 months: advisory only, with a hard 90-day term and explicit exit criteria; a full-time hire at this runway is a bet you cannot cover. 8–12 months: advisory first, with the full-time search opening only on a clear positive signal. Over 12–18 months with a proven motion: hire full-time and stop deliberating — every month of delay is compounding lost pipeline in a role with a six-to-nine-month time-to-impact.

Gate four — is the founder ready to hand over the number? This is the gate most often skipped and most often fatal. A founder who is not genuinely prepared to stop being the closer will undermine a full-time CRO within two quarters — overriding their calls, taking meetings around them, keeping the real forecast in a private tab. If that readiness is not there, an advisory who coaches the founder is the honest structure, and it is not a lesser choice.

Conversion signals, when the advisory should become a full-time hire: a documented and demonstrably repeatable playbook, coverage sustained above roughly 2.5x for a full quarter rather than a single good month, at least one non-founder rep hitting quota on that playbook, forecast accuracy inside a tolerable band, and funding that comfortably absorbs the comp package. Hold signals: coverage still under 2x at day 90 with the cause traced to demand rather than execution, the founder still closing the majority of revenue, runway under 8 months, or an ICP that shifted during the engagement and has not stabilized.

Related questions

What pipeline coverage ratio should a Series A company actually target?

Target 3–4x for the current quarter, working backward from your stage-weighted win rate. If you close 25% of qualified opportunities, 4x is the honest requirement. 2x only works at a 50% win rate, which is rare and usually indicates over-filtered pipeline rather than exceptional selling.

Can a fractional CRO fix a demand generation problem?

Not directly. They can diagnose it in 30 days and specify what to hire, but filling an empty top-of-funnel requires demand gen execution — content, outbound capacity, partnerships, paid channels. Hiring revenue leadership to solve a volume problem produces an expensive person managing an empty funnel.

How long should a CRO advisory engagement run before deciding?

Ninety days is the standard term and the right one. Thirty days produces a diagnosis, sixty produces process change, ninety produces a leading-indicator trend. Longer than two consecutive terms without a build-or-hold decision usually means the engagement has quietly become a permanent structure nobody chose.

Should the advisory be allowed to close deals?

No. Deal coaching, live-call participation, and joint calls for teaching are appropriate; carrying quota is not. An advisory closing deals hides the underlying process failure and leaves nothing behind when the term ends. Measure them on process artifacts and leading indicators instead.

What should the board see during the engagement?

A short recurring written update: true coverage by rep and segment, ranked stall reasons with evidence from deal reviews, what changed in process that period, and a standing build-or-hold recommendation. Surprises in week eleven are a failure of the engagement, not of the quarter.

FAQ

How do I tell whether sub-2x coverage is a product problem or a sales process problem?

Look at demo-to-close conversion and run a structured loss review on the last 10–15 deals that reached demo. Above 25% demo-to-close means the product resonates and the leak is upstream in volume or qualification. Below 15% means prospects are seeing the product and declining it, which points to fit, positioning, or pricing. Then read the loss reasons: a cluster on budget and timing is a qualification failure; a cluster on feature gaps or a specific competitor is a product and positioning problem that no revenue leader resolves.

Should I hire a full-time CRO with six months of runway and coverage under 2x?

No. The search alone takes two to four months, ramp takes another three, and the role's time-to-impact exceeds the runway you have. You would spend a meaningful share of remaining cash on a bet that cannot resolve before you need to raise. An advisory engagement diagnoses the leak in the first month and installs fixes in the second at a small fraction of that cost, and it produces the evidence a bridge or extension conversation actually requires.

What single metric should the advisory move first?

Median days-in-stage between demo and proposal. Long dwell there means the team is not driving buyers to a decision, and it is the most tractable thing to fix because it responds to process rather than headcount. A disciplined next-step rule — advance within roughly a week of the demo or re-qualify authority and timeline — is the standard intervention, and velocity gains there show up in coverage faster than anything on the demand side.

How do I know when the advisory should convert to a full-time hire?

Not on coverage alone. The real signal is whether the motion runs without them: a written playbook, at least one non-founder rep hitting quota using it, forecast accuracy inside a tolerable band, and coverage sustained above roughly 2.5x for a full quarter. If the advisory is still personally running deal reviews and the founder is still the primary closer, the process is not self-sustaining and converting just makes the dependency permanent and more expensive.

What does the advisory cost relative to a full-time CRO?

An advisory engagement typically runs at a small single-digit percentage of what a loaded full-time CRO costs in year one, and it commits you for a quarter rather than four. The comparison that matters is against monthly burn: the advisory is a rounding error, the full-time hire consumes a meaningful slice of annual runway. Ask for the fee structure — retainer, day rate, or project — and a 30-day termination clause in writing.

What should be in the engagement contract before signing?

A defined term of 60–90 days, a 30-day termination right for both sides, named deliverables such as a pipeline audit, qualification framework, forecast cadence, and a written build-or-hold recommendation, explicit exit criteria that define success numerically, a stated time commitment in days per month, and any conversion fee if you later hire them full-time. Ambiguity on the last item is where these relationships most often break down.

Sources

• https://www.saastr.com/how-much-pipeline-do-you-really-need/
• https://openviewpartners.com/blog/sales-pipeline-coverage/
• https://www.bvp.com/atlas/scaling-to-100-million
• https://a16z.com/the-sales-learning-curve/
• https://www.sequoiacap.com/article/sales-hiring/
• https://hbr.org/2017/05/how-to-shorten-your-sales-cycle
• https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights/the-b2b-elements-of-value
• https://www.gartner.com/en/sales/topics/sales-pipeline-management
• https://firstround.com/review/the-founders-guide-to-hiring-a-vp-of-sales/

Related on PULSE

• [How do you decide if a CRO advisory before a full-time hire is right for a Series A company when churn is rising on enterprise accounts?](/knowledge/q10589)
• [How do you decide if a CRO advisory before a full-time hire is right for a Series A company when sales and marketing are misaligned?](/knowledge/q10585)
• [How do you decide if a CRO advisory before a full-time hire is right for a Series A company when international expansion next year?](/knowledge/q10581)
• [How do you decide if a CRO advisory before a full-time hire is right for a Series A company when preparing for fundraise in six months?](/knowledge/q10577)
• [How do you decide if a CRO advisory before a full-time hire is right for a Series A company when VP Sales is strong but no GTM strategy owner?](/knowledge/q10573)
• [How do you decide if a CRO advisory before a full-time hire is right for a Series A company when RevOps exists but no revenue leader?](/knowledge/q10570)